SMMT — Summit Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.87bn
- $10.28bn
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering
Brief: Summit Therapeutics Announces Proposed Public Offering Of Common Stock
Summit drops as concerns over older patients cloud cancer trial data (updated)
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Corrected: Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)
Merck rises after co and partner Kelun's lung cancer combo meets late-stage trial goal
Merck rises after co and partner Kelun's lung cancer combo meets late-stage trial goal
Summit Therapeutics falls after interim results from lung cancer study
Summit Therapeutics Q1 adjusted loss narrows despite higher R&D costs
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Summit Therapeutics Q4 net loss widens on rise in expenses
Brief: Summit Therapeutics Q4 Net Income USD -219.2 Million
U.S. STOCKS ON THE MOVE-Lockheed Martin, ManpowerGroup, Parker-Hannifin
U.S. STOCKS ON THE MOVE-Lockheed Martin, ManpowerGroup, Parker-Hannifin,
U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
Summit rises after FDA accepts marketing application for lung cancer drug